MedTrace Logo

Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension

NCT02653222 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-05-09

No results posted yet for this study

Summary

In this study the investigators are going to assess the feasibility of this innovate technique of renal sympathetic denervation by translumbar access under ct-guidance.

To limit the potential impact on the kidney, the investigators chose a population of chronic renal failure patients on dialysis or renal transplant (with native kidneys still present) and having resistant treatment hypertension despite antihypertensive combination therapy well conducted.

The investigators expect to obtain a decrease of the blood pressure at the 24-hours ambulatory blood pressure monitoring (ABPM) one month after the sympathetic denervation.

Conditions

  • Hypertension Resistant to Conventional Therapy
  • Kidney Failure, Chronic

Interventions

PROCEDURE

Renal sympathicolysis

PROCEDURE

Ambulatory Blood Pressure Monitoring

1 month before and after surgery the patient will have an ABPM over 24h

RADIATION

Magnetic Resonance Angiography

1 month before and after surgery the patient will have a MRA

BIOLOGICAL

Blood test

complete blood count, blood platelets, coagulation profile, irregular agglutinins search

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Julien Ghelfi, Md · University Hospital, Grenoble

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02653222 on ClinicalTrials.gov